Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1146912

	registered interest
	date	30/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assurance, if any, they have received that medication brought from new sources other than the EU will meet the same standards as present.
	tabling member printed	Baroness Afshar
	uin	HL17886
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>All human medicines marketed in the United Kingdom must meet stringent requirements for quality, safety and efficacy set out in UK medicines legislation and supporting guidelines. These apply regardless of the source of the medicine.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA), the Government body responsible for the safety and licensing of medicines in the UK, regularly inspect pharmaceutical manufacturing plants in the UK and in third countries.</p><p>Regardless of the location of the site of manufacture, the manufacturer must demonstrate to the MHRA that the product is manufactured according to the registered UK licence (marketing authorisation) and to at least the minimum standard detailed in the European Union Guide to Good Manufacturing Practice.</p><p>In addition, each batch of medicine manufactured in a third country is tested within the UK on import and the manufacturing document reviewed by the license holders Qualified Person before being certified for release to the market.</p><p>All these measures will remain in place if the UK leaves the EU.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 14:37:53 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3847 label Biography information for Baroness Afshar

1146933

	registered interest
	date	30/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: EU Nationals
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether, in the event of a no-deal Brexit, EU frontier workers working and paying tax and National Insurance in the UK will be entitled to NHS treatment.
	tabling member printed	Baroness Hollins
	uin	HL17907
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>In a ‘no deal’ European Union exit, EU citizens living in another state but travelling regularly to and from the United Kingdom as a frontier worker on or before exit day will continue to be entitled for National Health Service treatment without charge.</p><p>The Government is aiming to agree with the EU or with individual Member States continuing the existing reciprocal healthcare arrangements after exit day until at least 31 December 2020. Where such agreement is reached, an EU citizen who becomes a frontier worker after exit day would be eligible for NHS treatment without charge, under the terms of that arrangement. Where no agreement is reached, a frontier worker from that country may be charged for their care unless an exemption applies or the service that they are accessing is one which is free for everyone.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 15:44:58 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4190 label Biography information for Baroness Hollins

1147649

	registered interest
	date	01/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Babies: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the report by Genetic Alliance UK Fixing the Present, Building for the Future: Newborn screening for rare conditions, published in July, in particular its finding that the UK tests for fewer conditions in new-borns in its new-born bloodspot screening programme than similar high income countries; and what plans they have to increase the number of serious conditions they test for.
	tabling member printed	Baroness Redfern
	uin	HL17975
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>In the United Kingdom, screening is an end to end service from test to treatment. This is not necessarily the case in other countries such as the United States of America. Therefore, comparisons with other health systems can be misleading.</p><p>In April 2014, the UK National Screening Committee (UK NSC) recommended extending the newborn bloodspot screening programme to include four additional conditions: maple syrup urine disease; homocystinuria; glutaric acidaemia type 1; and isovaleric acidaemia. The newborn blood spot screening is currently offered to all babies to identify nine conditions, as recommended by the UK NSC.</p><p>The UK NSC welcomes any new topic proposals through its annual call for topics. Using research evidence, pilot programmes and economic evaluation, the UK NSC assesses the evidence for programmes against a set of internationally recognised criteria. To ensure that screening is offered where the balance of benefit outweighs the harms.</p><p>In August 2019, the UK NSC published <em>Generation genome and the opportunities for screening programmes</em>. The report reflects the specific opportunities identified by each of the 11 population screening programmes, including the antenatal and newborn screening programmes. The report concluded that the advances in genomic technologies present exciting and potentially effective developments for screening programmes. Current and developing research and technology will be used to determine how, in future, genetics can best be used in screening. A copy of the report is attached.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:39:50 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Generation_genome_and_opportunities_for_screening_programmes.pdf title Generation_genome
	tabling member	4551 label Biography information for Baroness Redfern

1147651

	registered interest
	date	01/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to increase the uptake of checks for breast, bowel, and cervical diseases; and whether they intend to publish guidance to NHS trusts in England about ways in which such trusts can increase the uptake of such checks.
	tabling member printed	Baroness Redfern
	uin	HL17977
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>NHS England is committed to improving the uptake of national cancer screening programmes, for breast, bowel, and cervical cancer.</p><p>In January, NHS England published its Long Term Plan, which outlined its ambition to deliver improvements in the uptake of national cancer screening programmes. To support this process, NHS England has developed improving uptake action plans, which can be used by providers and the wider health system, to improve the performance of screening programmes.</p><p>The uptake action plans include proposals for reviewing and extending appointment hours (for example for breast cancer screening) and using data to inform strategies for improving uptake in those populations of greatest need. These plans are already available to commissioning teams and will be updated and reissued throughout the year.</p><p>National Health Service regions are currently developing implementation plans to deliver on these commitments. To provide robust oversight and assurance of delivery, NHS England has established national programme boards for each cancer screening programme area.</p><p>In addition, we expect the Sir Mike Richards’ Review of Screening report, due to be published soon, to identify additional opportunities to improve the uptake of breast, bowel, and cervical screening.</p><p>Further, Public Health England has been running ‘Be Clear on Cancer’ campaigns since 2011. These are designed to raise the public’s awareness of specific cancer symptoms; encourage people with those symptoms to go to the doctor; and diagnose cancer at an earlier stage, and therefore make it more treatable, and thereby improve cancer survival rates.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:40:48 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4551 label Biography information for Baroness Redfern

1147652

	registered interest
	date	01/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what consideration they have given to using (1) smartphone bookings, (2) text reminders, (3) evening appointments, and (4) accessible locations, for cancer screening appointments; and what assessment, if any, they have made of whether such measures would increase (a) the uptake of such screenings, and (b) early diagnosis.
	tabling member printed	Baroness Redfern
	uin	HL17978
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>NHS England recognises the importance of delivering public health services, including screening, which people find easy to access. This is why the NHS Long Term Plan and detailed improvement actions are about ensuring services are easy and convenient for people to use in order to deliver the Long Term Plan ambition on cancer to see 55,000 more people surviving cancer for five years in England each year from 2028.</p><p>The actions plans include real-world case studies which have demonstrated improvements in local areas. These case studies sit alongside widely published evidence which has been proven to deliver improvements in uptake. We expect these actions to have a positive impact on the uptake of screening.</p><p>Sir Mike Richards’ Review of Screening report is due to be published shortly which will identify additional opportunities to improve the uptake of breast, bowel, and cervical screening. In addition, NHSX is looking at possible improvements to screening IT systems, which should support the delivery of cancer screening programmes.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:41:24 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4551 label Biography information for Baroness Redfern

1146292

	registered interest
	date	25/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases: Surgery
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many heart operations they estimate will be cancelled by the NHS in the event of a no-deal Brexit due to a lack of availability of bio-aortic root replacement imports from Italy.
	tabling member printed	Lord Bassam of Brighton
	uin	HL17787
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products once we have left the EU. This includes the supply of bio-aortic root replacement devices.</p><p>The Department, as part of our EU exit preparations, is implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17788 question first answered 08/10/2019 15:43:55 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3504 label Biography information for Lord Bassam of Brighton

1146293

	registered interest
	date	25/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases: Surgery
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what alternative bio-aortic root replacement supply lines have been developed in the event of a no-deal Brexit interrupting imports from Italy.
	tabling member printed	Lord Bassam of Brighton
	uin	HL17788
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products once we have left the EU. This includes the supply of bio-aortic root replacement devices.</p><p>The Department, as part of our EU exit preparations, is implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17787 question first answered 08/10/2019 15:43:55 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3504 label Biography information for Lord Bassam of Brighton

1146294

	registered interest
	date	25/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to guarantee a continuous supply of insulin for those with type 1 diabetes in the event of a no-deal Brexit.
	tabling member printed	Lord Bassam of Brighton
	uin	HL17789
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products, including insulin, once we have left the EU.</p><p>The Department, as part of our EU exit preparations, is implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages.</p><p>As an example of the preparations being taken by industry to prepare for EU exit, all three suppliers of insulin have publicly stated that they have significantly increased their United Kingdom stockpiles, and have met the Government’s request that they hold at least six weeks’ worth of extra stock in addition to their usual operational stocks.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 15:45:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3504 label Biography information for Lord Bassam of Brighton

1146920

	registered interest
	date	30/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genito-urinary Medicine: Finance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the impact of the one per cent increase in the local authority Public Health Grant, announced in the Spending Round 2019, published on 4 September, on sexual health services.
	tabling member printed	Lord Black of Brentwood
	uin	HL17894
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>Local authority public health grant allocations for 2020/21 will be published in due course. It will be for local authorities themselves to determine how best to use these resources based on their assessment of local need and with regard to their statutory duties.</p><p>Local authorities are required by regulations to provide comprehensive open access sexual health services, including provision for sexually transmitted infection testing and treatment and contraception.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:40:11 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4171 label Biography information for Lord Black of Brentwood

1146921

	registered interest
	date	30/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what discussions they have had, and intend to have, with local authorities about ensuring PrEP is routinely commissioned as part of HIV prevention services.
	tabling member printed	Lord Black of Brentwood
	uin	HL17895
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:24:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4171 label Biography information for Lord Black of Brentwood